Establishment of prognosis prediction model after hematopoietic stem cell transplantation based on pretransplantation data

2023 Fiscal Year Final Research Report

• Project/Area Number: 20K07788
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52010:General internal medicine-related
• Research Institution: Osaka Metropolitan University (2022-2023); Osaka City University (2020-2021)
• Principal Investigator: Masayuki Hino 大阪公立大学, 大学院医学研究科, 教授 (50244637)
• Co-Investigator(Kenkyū-buntansha): 中前 博久 大阪公立大学, 大学院医学研究科, 准教授 (30364003) ; 幕内 陽介 大阪公立大学, 大学院医学研究科, 病院講師 (70881176)
• Project Period (FY): 2020-04-01 – 2024-03-31
• Keywords: 造血幹細胞移植 / 移植後シクロホスファミド / バイオマーカー

Outline of Final Research Achievements

Post-transplant cyclophosphamide (PTCy) haphloidentical hematopoietic stem cell transplantation (HSCT) has been found beneficial for refractory hematologic malignancies. In investigating biomarkers influencing HSCT outcomes, it was observed that in PTCy haphloidentical HSCT, the presence of the donor NK cell activating receptor NKG2D gene polymorphism rs1049174CC in the donor led to lower rates of relapse/progression. Elevated levels of NT-proBNP and BNP before transplantation were associated with decreased overall survival and increased non-relapse mortality. In AML/MDS patients, the pre-transplant liver index/height ratio on ultrasound examination was associated with relapse in non-remission patients. We are currently offering an application for calculating individualized hematopoietic stem cell transplant outcomes using machine learning.

Free Research Field

血液内科学

Academic Significance and Societal Importance of the Research Achievements

同種造血幹細胞移植前及び移植後のバイオマーカーを測定することで、合併症や移植予後の予測が可能となり、移植適応、移植ソース、移植方法の変更、早期の合併症対応により、移植成績の向上、患者QOLの改善、医療費の削減などに貢献できる可能性がある。